Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 18,750 Shares

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $77.94, for a total transaction of $1,461,375.00. Following the transaction, the chief executive officer now owns 379,534 shares of the company’s stock, valued at approximately $29,580,879.96. This represents a 4.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

William Lewis also recently made the following trade(s):

• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The shares were sold at an average price of $70.18, for a total transaction of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The shares were sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Stock Up 0.5 %

Shares of NASDAQ INSM opened at $81.44 on Thursday. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $81.96. The firm has a market capitalization of $14.57 billion, a price-to-earnings ratio of -14.67 and a beta of 1.11. The stock has a 50 day moving average price of $72.69 and a 200 day moving average price of $73.04. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Analysts Set New Price Targets

A number of research firms have recently weighed in on INSM. HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. boosted their price objective on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. Truist Financial reaffirmed a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, Bank of America boosted their target price on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $83.67.

Institutional Investors Weigh In On Insmed

Hedge funds have recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new stake in shares of Insmed in the third quarter valued at about $30,000. GAMMA Investing LLC increased its position in Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares during the period. Spire Wealth Management bought a new stake in shares of Insmed in the 4th quarter valued at about $47,000. Exchange Traded Concepts LLC lifted its position in shares of Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 411 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.